Dedicated to Discovery. Committed to Care.

Alexi Wright, MD

Hematology-Oncology Fellow
Dana-Farber Cancer Institute

To view this video "full-screen", click the button in the lower right of the player.

Read more about the study on the benefits of end-of-life conversations

History of advances

From achieving the first remissions of ALL and Wilm's tumor in pediatric patients in the '40s and '50s, to the development of Gleevec, the first "smart" cancer drug, in the late '90s, Dana-Farber researchers and clinicians have been at the forefront of discovery in cancer care and research. learn more